GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Beneish M-Score

aTyr Pharma (aTyr Pharma) Beneish M-Score : -4.10 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for aTyr Pharma's Beneish M-Score or its related term are showing as below:

LIFE' s Beneish M-Score Range Over the Past 10 Years
Min: -4.1   Med: 7.39   Max: 18.88
Current: -4.1

During the past 11 years, the highest Beneish M-Score of aTyr Pharma was 18.88. The lowest was -4.10. And the median was 7.39.


aTyr Pharma Beneish M-Score Historical Data

The historical data trend for aTyr Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Beneish M-Score Chart

aTyr Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 18.88 - - -4.10

aTyr Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -4.10

Competitive Comparison of aTyr Pharma's Beneish M-Score

For the Biotechnology subindustry, aTyr Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Beneish M-Score falls into.



aTyr Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of aTyr Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 6.0868+0.528 * 1+0.404 * 0.8547+0.892 * 0.034+0.115 * 0.7833
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 27.3115+4.679 * -0.179772-0.327 * 0.978
=-4.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2.44 Mil.
Revenue was 0 + 0.353 + 0 + 0 = $0.35 Mil.
Gross Profit was 0 + 0.353 + 0 + 0 = $0.35 Mil.
Total Current Assets was $102.99 Mil.
Total Assets was $120.65 Mil.
Property, Plant and Equipment(Net PPE) was $14.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.74 Mil.
Selling, General, & Admin. Expense(SGA) was $12.98 Mil.
Total Current Liabilities was $16.42 Mil.
Long-Term Debt & Capital Lease Obligation was $13.77 Mil.
Net Income was -14.76 + -11.34 + -12.338 + -11.951 = $-50.39 Mil.
Non Operating Income was 1.198 + 1.273 + 1.216 + 0.835 = $4.52 Mil.
Cash Flow from Operations was -11.062 + -9.559 + -12.01 + -0.59 = $-33.22 Mil.
Total Receivables was $11.78 Mil.
Revenue was 10.386 + 0 + 0 + 0 = $10.39 Mil.
Gross Profit was 10.386 + 0 + 0 + 0 = $10.39 Mil.
Total Current Assets was $80.87 Mil.
Total Assets was $95.79 Mil.
Property, Plant and Equipment(Net PPE) was $11.56 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.70 Mil.
Selling, General, & Admin. Expense(SGA) was $13.98 Mil.
Total Current Liabilities was $13.86 Mil.
Long-Term Debt & Capital Lease Obligation was $10.64 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.436 / 0.353) / (11.775 / 10.386)
=6.90085 / 1.133738
=6.0868

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10.386 / 10.386) / (0.353 / 0.353)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (102.992 + 14.046) / 120.653) / (1 - (80.871 + 11.557) / 95.786)
=0.029962 / 0.035057
=0.8547

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.353 / 10.386
=0.034

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.695 / (1.695 + 11.557)) / (2.741 / (2.741 + 14.046))
=0.127905 / 0.163281
=0.7833

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(12.979 / 0.353) / (13.982 / 10.386)
=36.767705 / 1.346235
=27.3115

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((13.767 + 16.416) / 120.653) / ((10.64 + 13.862) / 95.786)
=0.250164 / 0.255799
=0.978

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-50.389 - 4.522 - -33.221) / 120.653
=-0.179772

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

aTyr Pharma has a M-score of -4.10 suggests that the company is unlikely to be a manipulator.


aTyr Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (aTyr Pharma) Business Description

Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121